8AT.STU Aclaris Therapeutics Inc
- Market cap
- -
- P/E
- -
- P/B
- 4.92x
- ROE
- -66.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8AT.STU undervalued?
Graham numberThe Graham number of Aclaris Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aclaris Therapeutics Inc fundamental analysis
No fundamental analysis for Aclaris Therapeutics Inc yet.
Aclaris Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
Aclaris Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aclaris Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 10.1M | 5.53M | 6.48M | 6.76M | 29.8M | 31.2M | 18.7M | 7.83M | 7.25M |
| Gross Profit | 3.24M | 1.02M | 1.35M | 2.05M | 17.8M | 13.2M | 3.26M | 542K | 768K |
| Operating Income | -134M | -67.3M | -48.5M | -65.4M | -85.2M | -116M | -52.5M | -74.1M | -92.3M |
| EBITDA | -132M | -92.6M | -50.9M | - | -84.4M | -115M | -51.7M | -73.6M | -91.8M |
| Net Income | -133M | -101M | -51.0M | -90.9M | -86.9M | -88.5M | -132M | -64.9M | -82.7M |
| EPS | -3.22 | -2.44 | -1.13 | -1.48 | -1.30 | -1.25 | -1.22 | -0.54 | -0.59 |
| Balance Sheet | |||||||||
| Total Assets | 276M | 98.3M | 70.8M | 251M | 255M | 197M | 220M | 160M | 180M |
| Total Liabilities | 60.4M | 28.4M | 33.1M | 53.9M | 57.0M | 40.2M | 64.8M | 57.4M | 55.1M |
| Shareholders' Equity | 215M | 69.9M | 37.7M | 197M | 198M | 157M | 156M | 103M | 125M |
| Cash & Short-term Investments | 57.0M | 35.9M | 22.1M | 27.3M | 45.3M | 39.9M | 24.6M | 20.0M | 19.2M |
| Cash Flow | |||||||||
| Operating Cash Flow | -101M | -61.4M | -38.6M | -52.1M | -67.6M | -78.3M | -20.1M | -47.1M | -76.0M |
| Capital Expenditure | 1.36M | 1.23M | 453K | 308K | 605K | 1.31M | 35.9M | 111K | 142K |
| Free Cash Flow | -102M | -62.6M | -39.1M | -52.4M | -68.2M | -79.6M | -56.0M | -47.2M | -76.1M |
| Ratios | |||||||||
| ROE | -61.7% | -144.6% | -135.5% | -46.0% | -44.0% | -56.3% | -84.9% | -63.0% | -66.3% |
| ROA | -48.2% | -102.8% | -72.1% | -36.2% | -34.1% | -44.8% | -59.9% | -40.5% | -46.0% |
| Net Profit Margin | -1,315.4% | -1,827.8% | -787.0% | -1,344.0% | -292.1% | -283.1% | -705.5% | -829.6% | -1,140.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aclaris Therapeutics Inc dividends
Aclaris Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Who owns Aclaris Therapeutics Inc
Ownership data of Aclaris Therapeutics Inc is not available yet.
Aclaris Therapeutics Inc company profile
- Company name
- Aclaris Therapeutics Inc
- Ticker
- 8AT.STU
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- -
- Fiscal year end
- December
- Address
- Website
- -